Senior Pharma Consultant
23+ years of experience
As a Senior Pharma Consultant for Pharma Custom Intelligence, Amanda Micklus works with pharma and biotech clients on disease landscaping and market opportunity assessments involving both primary and secondary market research.
Amanda has experience in searching and mining Pharma Intelligence's portfolio of pharma intelligence solutions for valuable insights and regularly contributes content across multiple products including In Vivo, Scrip, and The Pink Sheet.
With a focus on research and analysis of corporate strategy and deal-making, Amanda provides analysis of market-moving events that influence business development at leading companies.
Her areas of expertise include big pharma licensing and immune-oncology deal-making, R&D strategies, and pharma diversification.
Prior to joining the Custom Intelligence team, Amanda was a Principal Analyst with Datamonitor Healthcare, and a Deals Analyst and Research Manager with Pharma’s biopharma and medtech deals database (now part of Biomedtracker).
Before joining Pharma Intelligence in 2005, Amanda worked as a market research analyst at specialty pharmaceutical company Purdue Pharma and had a previous role as a medical librarian/information searcher.
She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library and Information Science from Long Island University.
By Amanda Micklus 20 Jun 2022
As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.
Topic Cell & Gene Therapy
By Amanda Micklus 10 Apr 2019
The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.
Topic Cell & Gene Therapy
By Amanda Micklus 19 Jun 2017
In the developing pharma landscape, it’s important to consider all variables to create a winning portfolio strategy.
22 Jun 2021
04 Jan 2021